GC Green Cross Launches SGLT-2 Inhibitor Diabetes Treatment 'Neodapa'

Published 12 Apr.2023 10:03(KST)

GC Green Cross announced on the 12th the launch of the diabetes treatment drug ‘Neodapa Tablets’ in 5mg and 10mg, and ‘Polmindapa Extended-Release Tablets’ in 10/500mg and 10/1000mg.

GC Green Cross's diabetes treatment 'Neodapa Tablets' <br>[Photo by GC Green Cross]

GC Green Cross's diabetes treatment 'Neodapa Tablets'
[Photo by GC Green Cross]

Neodapa Tablets are a type 2 diabetes treatment belonging to the sodium-glucose co-transporter (SGLT)-2 inhibitor class, containing the active ingredient dapagliflozin. By inhibiting SGLT-2 in the kidneys, it reduces glucose reabsorption, thereby promoting the excretion of unabsorbed glucose through urine, resulting in a blood sugar-lowering effect. A GC Green Cross representative explained, "In particular, the 5mg Neodapa Tablet is a low-dose dapagliflozin product, which is expected to facilitate dose adjustment in the treatment of type 2 diabetes."

Neodapa Tablets are administered as an adjunct to diet and exercise therapy to improve blood glucose control in patients with type 2 diabetes. They can be used to lower blood sugar at all stages of type 2 diabetes, except in cases accompanied by moderate to severe chronic kidney disease.

The newly launched Polmindapa Extended-Release Tablets are a combination drug containing dapagliflozin and metformin. Metformin is a representative first-line drug for diabetes treatment that inhibits glucose production in the liver and reduces glucose absorption in the intestines, thereby improving insulin sensitivity. In patients with insufficient blood glucose control despite metformin use, the combined administration of dapagliflozin and metformin has been proven to provide an additional blood sugar-lowering effect.

A GC Green Cross representative stated, “Starting with this diabetes treatment launch, we will continuously expand our diabetes treatment lineup to establish ourselves as a leader in the domestic diabetes treatment market, which is estimated to be worth 1 trillion KRW.”